Introduction {#S1}
============

Retinal ganglion cells (RGCs) are the last cellular element of the retinal visual pathway and the sole neurons projecting outside the retina; their axons extend through the optic nerve (ON), the chiasm, and optic tract into the midbrain, targeting the superior colliculi and the lateral geniculate nucleus ([@B12]; [Figure 1](#F1){ref-type="fig"}). Preserving RGCs function is essential for the transmission of visual information to the central nervous system (CNS) and any damage altering the connection between eye and brain has severe consequences on vision. RGC loss occurs in several ocular pathologies, with glaucoma and diabetic retinopathy being the two major causes ([@B1]).
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Glaucoma is a worldwide leading cause of irreversible blindness ([@B60]). The term comprises of a spectrum of ocular conditions characterized by typical alterations of the ON head and distinct visual field defects. The neurodegenerative process often extends beyond the eye into the lateral geniculate nucleus and visual cortex, suggesting that central areas are involved ([@B36]). Age and high intraocular pressure (IOP) are the main risk factors; however, normal tension glaucoma (NTG) occurs in patients with physiological IOP and a portion of patients show progression even if IOP is maintained in the physiological range ([@B32]).

Several molecular mechanisms have been involved in RGC apoptosis (excitotoxicity, reduced neurotrophic support, inflammation, etc.) ([@B54]; [@B47]). Despite the wealth of preclinical studies showing efficacy for drugs targeting these pathways, almost all failed translation to the clinic, so effective treatment remains a therapeutic challenge.

Several pieces of evidence show that dysfunctional autophagy recurs in neurodegenerative diseases making this process an attractive venue for neuroprotective drug discovery ([@B34]). Here we review the current literature linking autophagy with RGC degeneration and the controversial outcomes obtained by manipulating autophagy in experimental glaucoma.

Autophagy Pathways {#S2}
==================

Autophagy, a lysosome-mediated degradation system, degrades cytoplasmic macromolecules with the aim to maintain a correct balance in the number of cytoplasmic components. The process is particularly challenging in neurons due to their high metabolic activity, their complex structure, and their inability to dilute toxic protein aggregates by cell division; this sensitivity further increases with aging as a result of reduced autophagy efficiency ([@B13]). Based on the mechanism of cargo delivery to lysosomes, three forms of autophagy can be distinguished: macroautophagy, chaperone mediated autophagy (CMA), and microautophagy.

Macroautophagy {#S2.SS1}
--------------

Macroautophagy requires the formation of a double membrane structure that recognizes and engulfs cytoplasmic fragments, proteins, and organelles ending in the formation of a vesicle called autophagosome. Several autophagy-related genes (known as Atg) participate in different steps of macroautophagy; autophagosome formation requires two conjugation events that lead to the formation of the Atg5-12-16 complex and the lipidation of the soluble form of Atg8 (LC3 in mammals), while the initial nucleation step requires a complex formed by Atg6 (beclin-1), AMBRA1, Vps34, Vps15, and Atg14L. Mature autophagosomes fuse with lysosomes, forming the autophagolysosomes; the internal membranes of autophagosomes are degraded together with the cargo, and the degradation products are then released into the cytoplasm and recycled for new processes ([@B42]).

Macroautophagy had initially been thought to be a bulk degradation pathway devoid of selectivity toward its substrates. It has, however, become clear that cargo sorting is present and it is conferred by cytosolic receptor proteins able to tether selective substrates to the nascent autophagosomes, acting as a bridge between the cargo and ATG8-family proteins ([@B65]). In mammalian cells the autophagy receptor protein binds ubiquitinated substrates; p62/sequestosome 1 (SQSTM1), NBR1, NDP52 and optineurin are four of the so far identified autophagy receptors ([@B20]). Furthermore, some macroautophagy processes are selective for the specific degradation of damaged organelles like mitochondria (e.g., mitophagy).

Macroautophagy activity inversely correlates with the activation of the mTOR complex 1 (mTORC1) that, when active, phospho-inhibits the ULK1 complex preventing autophagy ([@B56]). Conversely, the serine/threonine AMP activated kinase (AMPK) promotes autophagy through inhibition of mTORC1 and activation of ULK1 ([@B11]).

Mitophagy {#S2.SS2}
---------

Mitophagy mediates the physiological turnover of mitochondria and is responsible for the adaptation of the amount of mitochondria in response to environmental and metabolic changes ([@B38]). As a quality control mechanism, mitophagy is also responsible for the removal of defective mitochondria and it can be induced to inhibit mitochondria-dependent apoptosis ([@B35]).

Mitophagy regulatory pathways are distinct in that they are ubiquitination-mediated and mitophagy-receptor-mediated. The PINK-parkin pathway regulates ubiquitin-dependent mitophagy. Under normal conditions, PINK is rapidly cleaved, released into the cytosol, and degraded by proteasome; loss of mitochondrial membrane potential stabilizes PINK at the outer mitochondrial membrane (OMM), recruiting the E3 ligase parkin. In addition to parkin, other ubiquitin E3 ligases (i.e., Gp78, SMURF1, SIAH1, MUL1, and ARIH1) play a role in mitophagy regulation. Once localized on the mitochondrial surface, they generate ubiquitin chains that are recognized by autophagy adaptor proteins (i.e., optineurin, NBR1, and p62) that guide the engulfment of ubiquitinated mitochondria by the autophagosomes ([@B31]).

The receptor-mediated mitophagy relies on proteins localized at the OMM that act as mitophagy receptors and are able to interact with Atg8/LC3. In mammalian cells, OMM proteins NIX, BNIP3, and FUNDC1 -- which all have an LC3-interacting region (LIR) -- have been defined as mitophagy receptors and are involved in hypoxia-induced mitophagy ([@B30]). AMBRA1, a positive regulator of autophagy that stabilizes mTORC1 and the ULK1 complex, is partially localized at the mitochondria and can also act as mitophagy receptor ([@B3]). Neurons are highly vulnerable to mitochondrial impairment, and dysfunctional mitophagy has been linked with neurodegenerative conditions like Parkinson's and Alzheimer's diseases ([@B34]).

Chaperone-Mediated Autophagy {#S2.SS3}
----------------------------

Chaperone mediated autophagy differs from macro/microautophagy for several reasons: it is highly selective, it does not need the formation of vesicle for lysosomal delivery, single proteins are the only cargo, and they must be recognized by chaperones that mediate their direct translocation through the lysosomal membrane.

The high removal selectivity by CMA involves the formation of complexes between proteins bearing a CMA targeting motif (a pentapeptide sequence similar to KFERQ) and chaperones of the Hsp70 family; these complexes are recognized by the lysosome-associated membrane protein type-2A (LAMP2A) at the lysosomal membrane where the substrate proteins unfold and translocate in the lumen and are degraded by lysosomal hydrolase. Proteins that do not carry the KFERQ motif can also be degraded by CMA after post-translational modifications ([@B10]). LAMP2A acts as a limiting element for the activity of CMA, and changes in LAMP2A levels correlate with CMA activity ([@B5]).

Basal CMA can be detected in almost all mammalian cells, although each tissue shows a different level, suggesting that dependency on this pathway varies among cell types ([@B27]). As part of the cellular response to stressful conditions, CMA can be further induced by a variety of stimuli, like hypoxia ([@B18]) and oxidative stress ([@B22]).

Autophagy and RGC Degeneration {#S3}
==============================

Elevated IOP can cause direct mechanical stress to RGC axons together with ischemic effects due to the compression of the blood vessels supplying ON head. Furthermore, it might cause damage to the dorsal attachment of astrocytes at the ON head, causing loss of metabolic support and mechanical strength to RGC axons ([@B7]).

Increased LC3 immunoreactivity at the ganglion cell layer (GCL) and accumulation of LC3II has been shown between 6 and 24 h after a transient IOP increase in rats ([@B43]; [@B46]; [@B62]). In this same model, evidence of autophagy impairment due to calpain-mediated cleavage of beclin-1 was reported in the insulted retina ([@B53]).

The mice subjected to transient retinal ischemia in our group have shown a biphasic, reperfusion-time dependent modulation of autophagy. Autophagic flux experiments demonstrated that, in the injured retina, autophagy induction reached a peak 6 h after the insult, while autophagic flux reduced after 24 h; declined autophagic turnover was suggested by a decrease of ATG proteins (ATG4, ATG12-5, BECN1) and accumulation of p62-positive bodies in RGC cytoplasm ([@B55]). In this study, increased RGC loss was observed in mice with genetic impairment of basal autophagy due to the heterozygous ablation of AMBRA1 ([@B55]).

Impairment of the autophagic flux with an accumulation of p62 and autophagic vacuoles has been reported in RGC axons following chronic IOP elevation by laser photocoagulation ([@B24]). Similarly, an increase of autophagic vesicles was shown in the retina of chronic hypertensive rhesus monkeys; however, upregulation of lysosomal activity and an increase of LC3II and beclin-1 expression suggested activation, rather than impairment, of the autophagic flux ([@B9]).

Autophagy was significantly activated in a model of chronic hypertensive glaucoma induced by episcleral veins cauterization (EVC), as demonstrated by an accumulation of autophagosomes in the soma and dendrites of RGCs and upregulation of beclin-1 and LC3II/LC3I ratio. Inhibition of autophagy by 3-methyladenine (3-MA) decreased the number of apoptotic neurons in GCL, suggesting that autophagy induced cell death ([@B40], [@B39]). By contrast, after IOP elevation by laser photocoagulation, 3-MA exaggerated axonal degeneration, while the mTOR inhibitor rapamycin reduced axonal accumulation of p62 and exerted axonal protection against ON degeneration ([@B24]).

Our group has recently shown that subchronic systemic treatment with rapamycin sustained autophagy in retinas subjected to a transient increase of IOP and reduced RGC loss ([@B55]). Accordingly, pharmacological inhibition of mTOR afforded neuroprotection to RGCs following chronic ocular hypertension and suppressed apoptosis of primary RGCs induced by glutamate ([@B59]). Conversely, an acute systemic administration of rapamycin exacerbated RGC death induced by ON ischemia ([@B2]) and deletion of the negative regulator of mTOR, i.e., PTEN, in RGCs promoted ON regeneration and increased RGC survival after ON crush ([@B41]).

Following ON transection, a model mimicking the impairment of retrograde axonal transport of trophic factors occurring in glaucoma, upregulation of beclin-1 and LC3II expression was reported in whole retinas and isolated RGCs ([@B23]). A subsequent study showed that autophagy is activated in axotomized retinas and suggested a cytoprotective role of this pathway; indeed, genetic downregulation of autophagy, by RGC-specific deletion of Atg5 or Atg4B knocking down, was associated with reduced RGC survival, while rapamycin treatment increased the number of surviving RGCs ([@B51]).

An opposite conclusion was drawn by Koch and colleagues that showed a post-lesional Ca^2+^-dependent activation of autophagy with an accumulation of autophagosomes in RGC axons following ON crush; in this study, pharmacological inhibition of autophagy by 3-MA delayed axonal degradation ([@B26]).

Recently, a decrease of LC3II/LC3I ratio and increase of p62 after ON crush was shown to imply an impairment of the autophagy process in this model ([@B37]). p62 siRNA facilitates autophagy by preventing p62 aggregates accumulation ([@B28]); in a rat model of ON crush p62 siRNA offered better preservation of visual function and greater prevention of RGC apoptosis as compared to rapamycin treatment. This was mediated by a specific deactivation of mTORC1 without inhibition of mTORC2-mediated positive effects (i.e., Akt phosphorylation, stabilization of the blood ocular barrier, M2 macrophage polarization) ([@B63]).

In DBA/2J mice, a spontaneous ocular hypertensive model of glaucoma, an increased number of autophagosomes, higher LC3II/LC3I, and decreased LAMP1 were observed in myelinated ON axons. This observation was associated with increased mitochondrial damage and no changes in PINK or parkin levels, suggesting that the degenerating organelles may not be efficiently removed by mitophagy ([@B4]).

More recently, Hirt and colleagues monitored autophagy in the iridocorneal angle region and retina of DBA/2J and transgenic DBA/2J:GFP-LC3 mice; in both strains decreased LAMP1 and upregulation of LC3II and p62 were reported in the angle region, while decreased levels of all three proteins were shown in the RGC bodies, suggesting an overall slowed autophagic flux ([@B17]).

Mutation of the optineurin genes has been associated with an autosomal dominant form of hereditary NTG ([@B49]). Optineurin is recruited to damaged mitochondria following parkin and, subsequently, recruits LC3 resulting in autophagosomes formation around mitochondria. Alteration of these latter steps, as it has been shown for an ALS-associated optineurin mutant, leads to inefficient PINK-Parkin-associated mitophagy and pathological accumulation of damaged mitochondria ([@B64]). The E50K mutation is the most common optineurin mutation associated to NTG; increased LC3 immunoreactivity, detection of autophagosome, and autolysosome were reported in RGCs of E50K transgenic mice ([@B57]). Furthermore, E50K altered mitochondrial dynamics and induced mitochondrial fission and mitophagy in the axon of glial lamina of aged E50K transgenic mice and cultured primary RGCs ([@B58]).

Upregulation of parkin and optineurin was reported in the GCL of hypertensive rats; in this model, the number of unhealthy mitochondria and mitophagosomes were increased and it was associated with a higher LC3II to LC3I ratio and decreased LAMP1 two weeks following IOP elevation, suggesting a reduction of autophagosome turnover and local mitochondrial recycling ([@B8]). Overexpression of parkin reduced RGC loss, promoted optineurin expression, and partially restored mitophagy dysfunction in the ON ([@B8]). The mitochondrial uncoupling protein 2 (UCP2) reduces mitochondrial oxidative stress and exerts neuroprotective effects by uncoupling oxygen consumption from ATP synthesis ([@B50]). Deletion of UCP2 reduced RGC death in mice with chronic elevated IOP by increasing the level of mitophagy and facilitating mitochondrial function ([@B14]).

Trabecular Meshwork Autophagic Deregulation in Glaucoma {#S4}
=======================================================

Trabecular meshwork (TM), a tissue involved in maintaining IOP into physiological range, is constantly exposed to stresses such as oxidative, mechanical, and shear stress that, in the long term, may alter tissue function leading to higher resistance in aqueous humor outflow often associated with glaucoma. Porter and colleagues demonstrated that autophagy is induced in chronically stressed TM cells, however, the concomitant reduced acidification of the lysosomal compartment, improper cathepsin maturation, and decreased cathepsin B activity resulted in reduced autophagic flux ([@B45]). This same group compared the autophagic function of TM cells isolated from glaucomatous and age-matched donor eyes showing a mTOR-dependent dysregulation of autophagic pathway (i.e., lower basal levels of LC3II and p62) and autophagy response in glaucomatous TM cells ([@B44]). A recent study on human TM cells exposed to chronic oxidative stress reported protective effects of rapamycin that were associated with removal of damaged mitochondria, suggesting a protective role for autophagy in TM cells ([@B15]).

Autophagy is also activated in TM cells exposed to biaxial mechanical stretch and high pressure in a mTOR and BAG3 independent manner; interestingly, cyclic, but not static, mechanical stimulation of TM cells seems to activate a chaperone-assisted selective autophagy (CASA) ([@B16]), a selective tension-induced autophagy previously described in muscle ([@B61]).

The Interplay Between Macroautophagy and CMA {#S5}
============================================

Macroautophagy and CMA are both essential components of the stress response in mammalian cells and several studies suggest a reciprocal interplay so that changes in the activity of one will affect the contribution of the other to protein degradation. For instance, blockade of macroautophagy, both pharmacologically or knocking down Atg5 gene, results in CMA up-regulation under normal and stressed nutritional conditions ([@B21]). Furthermore, in several experimental systems, a sequential, rather than a concomitant, activation of these two forms of autophagy can be observed. For example, in liver and cultured fibroblasts, macroautophagy is activated during the first hours of starvation, while CMA takes over at later time points ([@B6]; [@B33]). An inverse order of activation has been reported in case of presence of misfolded proteins: CMA is activated first to degrade the substrate and, subsequently, macroautophagy comes into place to remove the multimeric complexes formed by the misfolded proteins ([@B48]; [@B19]).

The requirements for active CMA or the possibility to replace it with macroautophagy depends on the insult, the type of protein damage (aggregation *versus* unfolding), and the type of substrates (protein *versus* organelles). This implies that CMA and macroautophagy cannot completely compensate for each other's function.

However, this interplay between macroautophagy and CMA seems to be cell-type dependent. Indeed, in aged retinas and Atg5 deficient mice reduced activity of macroautophagy was accompanied by upregulation of the CMA markers LAMP2A and Hsp70; however, *in vitro* downregulation of CMA did not elicit macroautophagy activation in photoreceptor cells ([@B52]).

Discussion {#S6}
==========

The controversial results reported on the role of autophagy in insulted RGCs, with autophagy either protecting or promoting cell death (see [Table 1](#T1){ref-type="table"}), still leaves several questions on the clinical feasibility of targeting autophagy to achieve retinal neuroprotection. Interpretation of the results under an integrated hypothesis is further complicated by the use of different animal models, each mimicking a single aspect of the disease (i.e., hypoxic events, alteration of neurotrophin transportation, acute or chronic hypertension). Some of the answers may reside in the spatio-temporal regulation of the process and the interplay between the autophagy subtypes. Indeed, with autophagy being a dynamic process, the results should be interpreted considering the time selected after the initial insult and the neuronal compartment analyzed (axon *versus* soma). Another drawback of many publications is the lack of autophagic flux assay that limits the correct interpretation of the data ([@B25]). It must also be considered that several studies used *in vitro* and *in vivo* models expressing GFP-LC3, this can form aggregates that are often indistinguishable from autophagosomes by fluorescence microscopy and may also alter the physiological autophagosome turnover ([@B29]; [@B17]). Moreover, the available drugs modulating autophagy affect multiple pathways, making the isolation and interpretation of autophagy in the different experimental settings difficult.

###### 

Autophagy modulation in experimental models of glaucoma.

  Experimental model               Analyzed structure                                       Autophagy markers      Effects of autophagy modulators                      References                                                                    
  -------------------------------- -------------------------------------------------------- ---------------------- ---------------------------------------------------- ----------------------------------------------------------------------------- --------
  Retinal ischemia/reperfusion     Male wistar rats                                         Retina                 ↑ LC3II, ↑ autophagosomes                            3-MA prevents neuronal loss in GCL and reduces apoptotic markers              [@B43]
                                   Male Sprague-Dawley Rats                                 Retina                 ↑ LC3II (3 h)                                        Rapamycin increases the number of apoptotic cells in GCL                      [@B46]
                                   Male Sprague-Dawley Rats                                 Retina                 ↑ LC3II, ↑ autophagosomes                                                                                                          [@B62]
                                   Male wistar Rats                                         Retina                 ↓ LC3II, ↓ beclin-1                                                                                                                [@B53]
                                   Male C57BL/6J, Ambra1^+/gt31^, GFP-LC3 Mice              Retina                 ↑ LC3II (6h), ↓ LC3II (24 h) ↑ p62                   Rapamycin and fasting reduce RGC loss Ablation of AMBRA1 increases RGC loss   [@B55]
  Laser photocoagulation           Male wistar rats                                         Optic nerve            ↑ LC3II, ↑ p62, ↑ autophagosomes                     3-MA increases axonal degeneration Rapamycin reduces axonal degeneration      [@B24]
                                   Male and Female Rhesus Monkey                            Retina                 ↑ LC3II, ↑ LC3II/LC3I, ↑ beclin-1 ↑ autophagosomes                                                                                 [@B9]
  Episcleral veins cauterization   Male Sprague-Dawley Rats                                 Retina                 ↑ LC3II, ↑ LC3II/LC3I, ↑ beclin-1                    3-MA prevents neuronal loss in GCL                                            [@B40]
                                   Male Sprague-Dawley Rats                                 Retina                 ↑ LC3II/LC3I, ↑ beclin-1                             3-MA prevents RGC apoptosis                                                   [@B39]
                                   Sprague-Dawley Rats                                      Retina, Primary RGCs                                                        Rapamycin prevents RGC loss                                                   [@B59]
  Optic nerve transection          Male wistar rats                                         Retina, Primary RGCs   ↑ mRNA Atg5, Atg7, Atg12 ↑ beclin-1, ↑ LC3II (3 h)                                                                                 [@B23]
                                   GFP-LC3 Mice, Atg4B^--/--^ Mice, Atg5 ^flox/flox^ Mice   Retina                 ↑ LC3II, ↑ autophagosomes                            Rapamycin reduces RGC death                                                   [@B51]
  Optic nerve crush                Female wistar rats                                       Optic nerve            ↑ autophagosomes                                     3-MA delays axonal degradation                                                [@B26]
                                   Male wistar rats                                         Retina                 ↓ LC3II/LC3I, ↑ p62                                                                                                                [@B37]
                                   Male wistar rats                                         Retina                 ↑ mRNA p62, ↑ LC3II, ↑ LAMP1                         p62 siRNA and rapamycin prevents RGC apoptosis                                [@B63]
  DBA/2J Mice                                                                               Optic nerve            ↑ LC3II/LC3I, ↓ LAMP1, ↑ autophagosomes                                                                                            [@B4]
                                                                                            Retina                 ↑ LC3II, ↑ p62, ↓ LAMP1 in angle region              [@B17]                                                                        
                                                                                                                   ↓ LC3II, ↓ p62, ↓ LAMP1 in RGC bodies                                                                                              

Although it is clear that modulation of autophagy represents a consistent response of RGCs to detrimental insults, the availability of selective autophagy modulators and a detailed understanding of the contribution of the different autophagy pathways are required for future translation of experimental data into glaucoma therapy.
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